Journal of Microbial Pathogenesis

Kamal Uddin Saikh

Biography

My scientific career started in 1978 as a graduate student. My research activities encompassed the understanding of the immune system not only because of its intrinsic importance to human health and disease, but also because the immune system has evolved and elaborate strategies for recognition, communication, and adaption. My research is primarily focused on basic to more translational research. My laboratory skills include most aspects of immunology, cell biology, molecular biology, and microbiology. My research background and training encompass many aspects of immunology, microbiology and virology. During my scientific career, I have published with my colleagues more 36 publications in peer reviewed journals mostly as a first author or senior author. Currently I am serving as a reviewer in several journals including J. Immunology, Journal of Leukocyte Biology and as an editorial board of Journal of clinical and Cellular immunology. Beside academic publications, I also published my research discoveries as patents and Book Chapter with my colleagues on staphylococcal enterotoxin B (SEB) in the Text book of Military Medicine (in press). In addition to my academic experiences, I have also worked as a scientist at a pharmaceutical company (SmithKline Beecham Pharmaceuticals). Over the last 20 years of my research as a PI at USAMRIID is primarily focused on basic to more translational research with a particular emphasis on the understanding of innate immunity, immune regulation, and cell signaling in the context of assessing human immune responses (ex vivo) to several mission-relevant experimental vaccines and the discovery of target based therapeutics against exposure to bio-threat agents for the U.S. Army. Currently, as a PI, I am working on the antiviral activity of a lead MyD88 inhibitor potential for broad-spectrum use which also demonstrated therapeutic efficacy against SEB intoxication. My other research activities include”vaccines directed Against Yersinia pestis” and “Correlates of Human Immunity with exposure to biothreat agents such as B. mallei and B. pseudomallei from an appropriate animal model of infection and immune response to recombinant F1-V vaccine against Y. pestis